Please assess the completion status of the following clinical trial:

Trial Title: Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has clinically or laboratory supported Multiple Sclerosis with evidence of INO by quantitative neurophysiologic criteria or has a history of ON.~2. Subject is between the ages of 18-65.~3. Subject is able to understand the demands of the protocol, has had any questions answered and has voluntarily signed the informed consent prior to any study procedures.~4. Subject has a peak saccadic acceleration ratio (abducting eye/adducting eye) of greater than 2S.D. above the mean derived form a normal control group.~5. Subject is otherwise in good health, based on complete medical history and physical examination, including vital signs and ECG.~Exclusion Criteria:~1. Subject is a pregnant female (as determined by a urine pregnancy test), a lactating female, or a female of child-bearing potential, not sterilized and not using one of the following methods of birth control: oral or injectable contraceptive agent, implantable contraceptive device, or barrier method.~2. Subject has a history of hypertension or diabetes.~3. Subject has known allergy to ACTH.~4. The subject has any medical condition, including psychiatric disease that might interfere with the interpretation of the results or with the conduct of the study.~5. Subject has a history of drug or ethanol abuse within the past year.~6. Subject has a history of ischemic heart disease.~7. Subject has received an investigational drug within 30 days of screening.~8. In opinion of investigator, subject is unlikely to complete study for any reason.~9. The subject has abnormal clinical laboratory values or an abnormal ECG, without approval of the study monitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ACTHAR- placebo first (Type: EXPERIMENTAL): Placebo, 20 mg, 40 mg, 80 mg
- ACTHAR- placebo second (Type: EXPERIMENTAL): 20mg, Placebo, 40 mg, 80mg
- ACTHAR- placebo third (Type: EXPERIMENTAL): 20 mg, 40 mg, Placebo, 80 mg
- ACTHAR- placebo fourth (Type: EXPERIMENTAL): 20 mg, 40 mg, 80 mg, Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).